These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24303008)

  • 61. Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats.
    Forget B; Barthélémy S; Saurini F; Hamon M; Thiébot MH
    Psychopharmacology (Berl); 2006 Nov; 189(1):59-69. PubMed ID: 16969683
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cannabinoid receptor interacting protein suppresses agonist-driven CB
    Blume LC; Leone-Kabler S; Luessen DJ; Marrs GS; Lyons E; Bass CE; Chen R; Selley DE; Howlett AC
    J Neurochem; 2016 Nov; 139(3):396-407. PubMed ID: 27513693
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat.
    Liu WJ; Jin HY; Park JH; Baek HS; Park TS
    Eur J Pharmacol; 2010 Jul; 637(1-3):70-6. PubMed ID: 20406631
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Involvement of the cannabinoid CB1 receptor in modulation of dopamine output in the prefrontal cortex associated with food restriction in rats.
    Dazzi L; Talani G; Biggio F; Utzeri C; Lallai V; Licheri V; Lutzu S; Mostallino MC; Secci PP; Biggio G; Sanna E
    PLoS One; 2014; 9(3):e92224. PubMed ID: 24632810
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233.
    Dhawan J; Deng H; Gatley SJ; Makriyannis A; Akinfeleye T; Bruneus M; Dimaio AA; Gifford AN
    Synapse; 2006 Aug; 60(2):93-101. PubMed ID: 16715483
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
    Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
    Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
    [TBL] [Abstract][Full Text] [Related]  

  • 68. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
    Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
    Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice.
    Lazzari P; Sanna A; Mastinu A; Cabasino S; Manca I; Pani L
    Behav Brain Res; 2011 Mar; 217(2):432-8. PubMed ID: 21074566
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacological modulation of the endocannabinoid signalling alters binge-type eating behaviour in female rats.
    Scherma M; Fattore L; Satta V; Businco F; Pigliacampo B; Goldberg SR; Dessi C; Fratta W; Fadda P
    Br J Pharmacol; 2013 Jun; 169(4):820-33. PubMed ID: 23072421
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Low dosage of rimonabant leads to anxiolytic-like behavior via inhibiting expression levels and G-protein activity of kappa opioid receptors in a cannabinoid receptor independent manner.
    Zádor F; Lénárt N; Csibrány B; Sántha M; Molnár M; Tuka B; Samavati R; Klivényi P; Vécsei L; Marton A; Vizler C; Nagy GM; Borsodi A; Benyhe S; Páldy E
    Neuropharmacology; 2015 Feb; 89():298-307. PubMed ID: 25446673
    [TBL] [Abstract][Full Text] [Related]  

  • 72. 3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.
    Wiley JL; Selley DE; Wang P; Kottani R; Gadthula S; Mahadeven A
    J Pharmacol Exp Ther; 2012 Feb; 340(2):433-44. PubMed ID: 22085649
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Effects of Chronic Alcohol Exposure on the Modulation of Ischemia-Induced Glutamate Release via Cannabinoid Receptors in the Dorsal Hippocampus.
    Zheng L; Wu X; Dong X; Ding X; Song C
    Alcohol Clin Exp Res; 2015 Oct; 39(10):1908-16. PubMed ID: 26343919
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pretreatment with subeffective doses of Rimonabant attenuates orexigenic actions of orexin A-hypocretin 1.
    Crespo I; Gómez de Heras R; Rodríguez de Fonseca F; Navarro M
    Neuropharmacology; 2008 Jan; 54(1):219-25. PubMed ID: 17889909
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics and role in influencing neurochemical phenotype.
    Burdyga G; Varro A; Dimaline R; Thompson DG; Dockray GJ
    Am J Physiol Gastrointest Liver Physiol; 2010 Jul; 299(1):G63-9. PubMed ID: 20430875
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The hypothermic response to bacterial lipopolysaccharide critically depends on brain CB1, but not CB2 or TRPV1, receptors.
    Steiner AA; Molchanova AY; Dogan MD; Patel S; Pétervári E; Balaskó M; Wanner SP; Eales J; Oliveira DL; Gavva NR; Almeida MC; Székely M; Romanovsky AA
    J Physiol; 2011 May; 589(Pt 9):2415-31. PubMed ID: 21486787
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats.
    McLaughlin PJ; Winston K; Swezey L; Wisniecki A; Aberman J; Tardif DJ; Betz AJ; Ishiwari K; Makriyannis A; Salamone JD
    Behav Pharmacol; 2003 Dec; 14(8):583-8. PubMed ID: 14665975
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).
    van Diepen H; Schlicker E; Michel MC
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Oct; 378(4):345-69. PubMed ID: 18654765
    [TBL] [Abstract][Full Text] [Related]  

  • 79. The inverse agonist of CB1 receptor SR141716 blocks compulsive eating of palatable food.
    Dore R; Valenza M; Wang X; Rice KC; Sabino V; Cottone P
    Addict Biol; 2014 Sep; 19(5):849-61. PubMed ID: 23587012
    [TBL] [Abstract][Full Text] [Related]  

  • 80. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569.
    Gamage TF; Ignatowska-Jankowska BM; Wiley JL; Abdelrahman M; Trembleau L; Greig IR; Thakur GA; Tichkule R; Poklis J; Ross RA; Pertwee RG; Lichtman AH
    Behav Pharmacol; 2014 Apr; 25(2):182-5. PubMed ID: 24603340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.